Novartis Pluvicto (lutetium (177Lu) vipivotide tetraxetan) receives MHRA authorisation for new indication for eligible patients...

ENHERTU Type II Variation Application validated in the EU as post-neoadjuvant treatment for patients with...

Hengrui Medicine’s HER2 ADC, Trastuzumab Ruikang, has been included in the Breakthrough Therapy List for...

Alphamab Oncology announces the first patient dosed in a phase 3 clinical study for colorectal...

BostonGene announces strategic collaboration with Daiichi Sankyo to accelerate drug development through AI-driven multimodal analytics

Affibody signs Letter of Intent with SHINE Technologies for supply of Lutetium-177